Page 18 - 《中国药房》2023年11期

Obes Metab，2012，14（6）：546-554. glutide safety and efficacy in patients with non-alcoholic
[45] BUSE J B，GARBER A，ROSENSTOCK J，et al. Liraglu‐ steatohepatitis （LEAN）：a multicentre，double-blind，ran‐
tide treatment is associated with a low frequency and mag‐ domised，placebo-controlled phase 2 study[J]. Lancet，
nitude of antibody formation with no apparent impact on 2016，387（10019）：679-690.
glycemic response or increased frequency of adverse [52] FLINT A，ANDERSEN G，HOCKINGS P，et al. Ran‐
events：results from the Liraglutide Effect and Action in domised clinical trial：semaglutide versus placebo reduced
Diabetes （LEAD） trials[J]. J Clin Endocrinol Metab， liver steatosis but not liver stiffness in subjects with non-
2011，96（6）：1695-1702. alcoholic fatty liver disease assessed by magnetic reso‐
[46] DUNLAY S M，GIVERTZ M M，AGUILAR D，et al. nance imaging[J]. Aliment Pharmacol Ther，2021，54（9）：
Type 2 diabetes mellitus and heart failure：a scientific 1150-1161.
statement from the American Heart Association and the [53] KUCHAY M S，KRISHAN S，MISHRA S K，et al. Effect
Heart Failure Society of America：this statement does not of dulaglutide on liver fat in patients with type 2 diabetes
represent an update of the 2017 ACC/AHA/HFSA heart and NAFLD：randomised controlled trial （D-LIFT trial）
failure guideline update[J]. Circulation，2019，140（7）： [J]. Diabetologia，2020，63（11）：2434-2445.
e294-e324. [54] BODE B W，BRETT J，FALAHATI A，et al. Comparison
[47] WHARTON S，DAVIES M，DICKER D，et al. Managing of the efficacy and tolerability profile of liraglutide，a
the gastrointestinal side effects of GLP-1 receptor agonists once-daily human GLP-1 analog，in patients with type 2
in obesity：recommendations for clinical practice[J]. Post‐ diabetes ≥65 and ＜65 years of age：a pooled analysis
grad Med，2022，134（1）：14-19. from phase Ⅲ studies[J]. Am J Geriatr Pharmacother，
[48] WILDING J P H，BATTERHAM R L，CALANNA S，et 2011，9（6）：423-433.
al. Once-weekly semaglutide in adults with overweight or [55] KUANG J，ZHU J K，LIU S Y，et al. Efficacy and safety
obesity[J]. N Engl J Med，2021，384（11）：989-1002. of once-weekly dulaglutide in elderly Chinese patients
[49] 中华医学会内分泌学分会，中华医学会糖尿病学分会 . with type 2 diabetes：a post hoc analysis of AWARD-CHN
中国成人 2 型糖尿病合并非酒精性脂肪性肝病管理专 studies[J]. Diabetes Ther，2020，11（10）：2329-2339.
家共识[J]. 中华内分泌代谢杂志，2021，37（7）：589-598. [56] RACCAH D，MIOSSEC P，ESPOSITO V，et al. Efficacy
[50] DONG Y J，LYU Q G，LI S Y，et al. Efficacy and safety of and safety of lixisenatide in elderly （≥65 years old） and
glucagon-like peptide-1 receptor agonists in non-alcoholic very elderly （≥75 years old） patients with type 2 diabe‐
fatty liver disease：a systematic review and meta-analysis tes：an analysis from the GetGoal phase Ⅲ programme[J].
[J]. Clin Res Hepatol Gastroenterol，2017，41（3）： Diabetes Metab Res Rev，2015，31（2）：204-211.
284-295. （收稿日期：2023-03-20 修回日期：2023-04-26）
[51] ARMSTRONG M J，GAUNT P，AITHAL G P，et al. Lira‐ （编辑：刘明伟）

· 1292 · China Pharmacy 2023 Vol. 34 No. 11 中国药房 2023年第34卷第11期